Paroxetine Low-Dose (Brisdelle): The Complete HRT Guide

Quick Reference Card

Overview / What Is Paroxetine Low-Dose (Brisdelle)?

The Basics

Brisdelle is a low-dose version of the antidepressant paroxetine, repurposed specifically for treating hot flashes and night sweats in menopausal women. It contains just 7.5 mg of paroxetine mesylate, which is substantially lower than the 20 to 60 mg doses used to treat depression, anxiety, and other psychiatric conditions. At this low dose, it works differently in practice: the goal is not to treat a mood disorder but to help stabilize the part of your brain that controls body temperature regulation.

When estrogen levels decline during menopause, the brain's thermostat (located in the hypothalamus) becomes overly sensitive to small changes in core body temperature. This triggers hot flashes and night sweats, sometimes dozens of times a day. Serotonin plays a role in regulating this thermostat, and by increasing serotonin availability, paroxetine appears to help widen the temperature range your body can tolerate without triggering a hot flash.

Brisdelle was approved by the FDA in June 2013, making it the first non-hormonal prescription treatment specifically approved for menopausal vasomotor symptoms. It was developed for women who cannot take hormone therapy (because of breast cancer history, blood clot risk, cardiovascular disease, or other contraindications) or who prefer not to use hormones. Since then, newer non-hormonal options have emerged, including fezolinetant (Veozah) and elinzanetant (Lynkuet), both neurokinin 3 receptor antagonists. However, Brisdelle remains a widely used option, particularly because generic paroxetine mesylate 7.5 mg capsules are now available.

It is important to understand that Brisdelle is not the same as taking Paxil for depression. The dose is different, the indication is different, and the side effect profile at this low dose is notably milder than what is typically associated with higher-dose SSRI therapy.

The Science

Paroxetine mesylate 7.5 mg (Brisdelle, NDA 204516) is an orally administered selective serotonin reuptake inhibitor formulated at a subtherapeutic psychiatric dose specifically for the treatment of moderate to severe vasomotor symptoms associated with menopause [1]. The compound received FDA approval on June 28, 2013, following two pivotal Phase 3 randomized, double-blind, placebo-controlled trials (NCT01361308 and NCT01101841) enrolling 1,174 postmenopausal women [2].

The approval was notable for several reasons. The FDA advisory committee (Reproductive Health Drugs Advisory Committee) initially voted 10-4 against approval, citing the modest magnitude of benefit over placebo. The FDA ultimately overruled this recommendation, determining that even modest reductions in VMS frequency and severity represented a clinically meaningful benefit for women who lacked non-hormonal treatment options [3].

Paroxetine mesylate is pharmacologically equivalent to paroxetine hydrochloride (Paxil, Pexeva) in terms of the active moiety but uses the mesylate salt form. Each 7.5 mg capsule contains 9.69 mg of paroxetine mesylate, equivalent to 7.5 mg of paroxetine free base [1]. The lower dose was specifically selected to provide VMS efficacy while minimizing the dose-dependent side effects associated with psychiatric doses, including weight gain, sexual dysfunction, and severe discontinuation symptoms [4].

The Menopause Society (formerly NAMS) classifies SSRIs/SNRIs as Level I evidence (recommended) for non-hormonal VMS management, with paroxetine mesylate 7.5 mg being the only FDA-approved agent in this class for this indication [5].

Medical / Chemical Identity

Physical Properties:

• Off-white powder
• Melting point: 147-150C
• Solubility: >1 g/mL in water

Formulation:

• 7.5 mg pink capsules printed with "BRISDELLE" and "7.5 mg"
• Inactive ingredients: dibasic calcium phosphate, sodium starch glycolate, magnesium stearate, gelatin, titanium dioxide, FD&C Yellow #6, FD&C Red #3, FD&C Red #40, shellac, black iron oxide

Related Paroxetine Products (higher doses, different indications):

• Paxil (paroxetine HCl): 10 mg, 20 mg, 30 mg, 40 mg tablets; approved for MDD, OCD, panic, GAD, SAD, PTSD
• Paxil CR (paroxetine HCl controlled-release): 12.5 mg, 25 mg, 37.5 mg
• Pexeva (paroxetine mesylate): 10 mg, 20 mg, 30 mg, 40 mg tablets; approved for MDD, OCD, panic, GAD

Mechanism of Action

The Basics

The exact way Brisdelle reduces hot flashes is not fully understood, but researchers have a working theory. Your brain has a temperature control center in the hypothalamus that works like a thermostat. In premenopausal women, this thermostat tolerates a comfortable range of body temperature changes without triggering a response. During menopause, declining estrogen levels cause this comfort zone to narrow dramatically. Even tiny increases in core body temperature (as small as a fraction of a degree) can trigger a full-blown hot flash: blood vessels dilate, sweating begins, and you feel an intense wave of heat.

Serotonin is one of the chemical messengers that helps regulate this thermostat. When estrogen levels fall, serotonin activity in the hypothalamus changes, contributing to the narrowed thermoneutral zone. By blocking the reuptake of serotonin (keeping more of it available in the brain), paroxetine appears to help widen this zone back toward normal, so your body does not overreact to minor temperature fluctuations.

This is why Brisdelle works differently from hormone therapy. Rather than replacing the estrogen your body is no longer producing, it targets the downstream consequence (the malfunctioning thermostat) through a different chemical pathway. It does not affect estrogen levels, progesterone levels, or any hormonal axis.

The Science

Paroxetine is a potent and highly selective inhibitor of neuronal serotonin (5-HT) reuptake at the serotonin transporter (SERT), with weak effects on norepinephrine and dopamine reuptake. In vitro radioligand binding studies demonstrate that paroxetine has minimal affinity for muscarinic, alpha-1, alpha-2, beta-adrenergic, dopamine D2, 5-HT1, 5-HT2, and histamine H1 receptors [1].

The mechanism by which serotonin reuptake inhibition reduces vasomotor symptoms is hypothesized to involve modulation of the hypothalamic thermoregulatory center. In the preoptic area of the hypothalamus, declining estradiol levels during menopause are associated with alterations in serotonergic neurotransmission, including changes in 5-HT2A receptor expression and tryptophan hydroxylase activity [6]. These changes contribute to a narrowing of the thermoneutral zone from approximately 0.4C to near zero, meaning that minimal core temperature elevations trigger inappropriate heat dissipation responses (peripheral vasodilation, sweating, and subjective flushing) [7].

Serotonergic neurons in the hypothalamus interact with kisspeptin/neurokinin B/dynorphin (KNDy) neurons, which are now recognized as central mediators of the thermoregulatory dysfunction underlying menopausal VMS. The newer NK3 receptor antagonists (fezolinetant, elinzanetant) target these KNDy neurons more directly, while SSRIs like paroxetine modulate the thermoregulatory circuit upstream through serotonergic pathways [8].

Paroxetine is also a potent irreversible inhibitor of cytochrome P450 2D6 (CYP2D6), which is clinically significant for drug interactions but unrelated to its VMS mechanism of action [1].

Pathway & System Visualization

Pharmacokinetics / Hormone Physiology

The Basics

When you swallow a Brisdelle capsule, the paroxetine is completely absorbed from your digestive tract. It takes about 6 hours to reach its peak level in your bloodstream, and it stays active in your body for roughly 21 hours (its half-life). This is why once-daily dosing at bedtime is sufficient.

Because paroxetine is metabolized primarily by a liver enzyme called CYP2D6, and paroxetine itself blocks this same enzyme, the drug essentially slows down its own breakdown. This means that after about 2 weeks of daily use, drug levels in your blood reach a steady state that is higher than what you would expect from a single dose. This is normal and expected.

Taking Brisdelle with or without food does not significantly affect how well it is absorbed. The bedtime dosing recommendation is based on the clinical trials rather than pharmacokinetic necessity, and may help any mild drowsiness serve as a sleep aid rather than a daytime nuisance.

One important note: about 7-10% of the population has a genetic variation that makes their CYP2D6 enzyme work slowly or not at all (called "poor metabolizers"). These individuals will have significantly higher blood levels of paroxetine. The clinical trials did not specifically adjust for this, but providers should be aware.

The Science

Absorption: Paroxetine mesylate is completely absorbed after oral administration. Following a single 7.5 mg dose in healthy adults, Tmax is approximately 6 hours (range 3-8 hours) with a Cmax of 4.4 ng/mL [1].

Steady State: Achieved within approximately 14 days of once-daily administration. At steady state, Cmax is 12.8 ng/mL and AUC(0-24) is 225 ng.h/mL, reflecting accumulation due to CYP2D6 autoinhibition [1].

Distribution: Paroxetine distributes extensively throughout the body, including the central nervous system. Approximately 95% is bound to plasma proteins, with 1% present in free form [1].

Metabolism: Extensively metabolized via CYP2D6-mediated oxidation and methylation. Principal metabolites are polar conjugates with approximately 1/50th the serotonin reuptake inhibition potency of the parent compound. Paroxetine is a potent mechanism-based (irreversible) inhibitor of CYP2D6, resulting in nonlinear pharmacokinetics at steady state [1][9].

Elimination: Approximately 64% excreted in urine (2% unchanged parent compound) and 36% in feces (<1% unchanged). Mean elimination half-life is approximately 21 hours [1].

CYP2D6 Poor Metabolizers: At steady state, CYP2D6 poor metabolizers demonstrate approximately 10-fold higher Cmax and AUC compared to extensive metabolizers. This has significant implications for both efficacy and safety in this pharmacogenomic subpopulation [1].

Effect of Food: No clinically significant effect on absorption [1].

Knowing the pharmacokinetics is the foundation. Seeing how your own body responds to your specific protocol turns that knowledge into actionable insight. Doserly correlates your dosing schedule with how you feel day to day, helping you and your provider identify whether your current route, timing, and dose are working optimally.

The app's analytics can surface patterns you might not notice on your own, like whether symptoms correlate with the end of a patch cycle or whether splitting an oral dose changes how you feel in the afternoon. Data like this makes dose adjustments more precise and less guesswork.

Research & Clinical Evidence

The Basics

The evidence supporting Brisdelle comes primarily from two large clinical trials and subsequent analyses, plus a growing body of meta-analyses and clinical reviews.

In the pivotal trials, over 1,100 postmenopausal women who were experiencing at least 7-8 moderate to severe hot flashes per day were randomly assigned to receive either Brisdelle 7.5 mg or a placebo pill at bedtime. Across both trials, women taking Brisdelle experienced statistically significant reductions in both the number and severity of their hot flashes compared to placebo. The effect appeared within the first 4 weeks and was maintained through 24 weeks of treatment.

A 2019 meta-analysis combining data from five randomized trials (1,482 women total) confirmed that low-dose paroxetine reduced hot flashes by approximately 8 fewer episodes per week compared to placebo. This held true for both women who went through menopause naturally and those who experienced surgical menopause.

Sleep improvements were also documented: women on Brisdelle had fewer nighttime awakenings caused by VMS and gained about 30-37 extra minutes of sleep per night compared to placebo. Importantly, this sleep improvement appeared to be secondary to hot flash reduction (fewer night sweats waking you up) rather than a direct sedative effect.

The North American Menopause Society classifies SSRIs and SNRIs as Level I evidence (the highest quality) for non-hormonal VMS treatment, and specifically notes that paroxetine 7.5 mg is the only FDA-approved agent in this class.

The Science

Pivotal Phase 3 Trials (Simon et al., 2013):

Two multicenter, randomized, double-blind, placebo-controlled Phase 3 trials enrolled 1,174 postmenopausal women (mean age 55, approximately 65% Caucasian, 33% African American, 18% surgically menopausal). Participants required a minimum of 7-8 moderate to severe VMS per day (>50/week) for 30 days prior to enrollment [2].

Study 1 (12-week, NCT01361308): Achieved 3 of 4 co-primary endpoints. Significant reductions in VMS frequency at Weeks 4 (P < 0.0001) and 12 (P < 0.0001) and severity at Week 4 (P = 0.0090). Severity at Week 12 showed a trend but did not reach statistical significance [2].

Study 2 (24-week, NCT01101841): Achieved all 4 co-primary endpoints. Significant reductions in VMS frequency at Weeks 4 (P = 0.0001) and 12 (P = 0.0001) and severity at Weeks 4 (P = 0.0452) and 12 (P = 0.0114). Persistence of benefit was demonstrated through Week 24 (P = 0.006) [2].

Meta-Analysis (Riemma et al., 2019):

Systematic review of 5 RCTs (1,482 women, paroxetine 7.5-12.5 mg) found a significant reduction in hot flush frequency: mean difference -7.97 [-10.51, -5.42] episodes/week versus placebo. Significant heterogeneity (I2 = 90%) was noted, attributable primarily to dose differences (7.5 mg vs 12.5 mg) between trials. Subgroup analyses showed efficacy in both physiological (MD -7.89) and surgical (MD -7.63) menopause [10].

Sleep Analysis (Pinkerton et al., 2015):

Pooled analysis of sleep data from both Phase 3 trials (n = 1,174). Paroxetine 7.5 mg significantly reduced VMS-attributed nighttime awakenings: 39% reduction vs 28% for placebo at Week 4 (P = 0.0049), sustained through 24 weeks (62% vs 43%, P < 0.0001). Sleep duration increased by +31 to +37 minutes per night compared to +16 to +27 minutes for placebo. No significant differences in sleep-onset latency or somnolence were observed, indicating the sleep benefit is secondary to VMS reduction rather than direct sedation [11].

Effect Size Contextualization:

The NAMS 2023 position statement characterizes SSRIs/SNRIs as producing "mild to moderate improvements in VMS," with paroxetine 7.5 mg demonstrating approximately 10-25% greater reduction in VMS frequency versus placebo [5]. This is a more modest effect than hormone therapy (which typically reduces VMS frequency by 75-95%) but represents a clinically meaningful option for women who cannot use hormones.

Evidence & Effectiveness Matrix

The following matrix scores the 20 HRT symptom/outcome categories using Evidence Strength (from clinical research) and Reported Effectiveness (from community data) where available.

Categories Not Scored (insufficient data for this non-hormonal SSRI):
Cognitive Function, Genitourinary Health (GSM), Bone Health & Osteoporosis, Cardiovascular Health, Metabolic Health & Insulin Sensitivity, Body Composition & Weight, Joint & Musculoskeletal Health, Skin Hair & Appearance, Breast Cancer Risk, Endometrial Safety, Thrombotic Risk, Menstrual & Reproductive, Other Physical Symptoms.

Note: As a non-hormonal treatment, paroxetine 7.5 mg does not affect estrogen, progesterone, or other hormone levels and therefore does not provide the systemic benefits of hormone therapy on bone, cardiovascular, genitourinary, or metabolic health.

Benefits & Therapeutic Effects

The Basics

The primary benefit of Brisdelle is reducing hot flashes and night sweats. In clinical trials, women experienced meaningful reductions in both how often hot flashes occurred and how severe they were. Many women notice improvement within the first 2 to 4 weeks, with the effect building and stabilizing over time.

Beyond the primary VMS benefit, women taking Brisdelle often report improved sleep quality. This is not because the drug is sedating; rather, when night sweats decrease, you wake up less frequently and sleep longer. In the clinical trials, women gained an average of about 30 extra minutes of sleep per night. For someone who has been waking up multiple times nightly, drenched in sweat, that improvement can feel transformative.

Some women also notice improvements in mood and anxiety at the 7.5 mg dose, though these were not formal study endpoints. Since paroxetine is an antidepressant at higher doses, it is plausible that even low doses have some mood-stabilizing effects, though this has not been rigorously studied in the menopause context specifically.

A key advantage of Brisdelle over hormone therapy is what it does not do: it does not increase breast cancer risk, does not increase blood clot risk, and does not require endometrial monitoring. For women with a history of breast cancer, blood clots, or other conditions that make hormone therapy inadvisable, this is a significant benefit in itself.

The Science

Vasomotor Symptom Reduction:
The pivotal trials demonstrated 33-65% reductions in hot flash frequency with 6-12 weeks of treatment, compared to 17-38% reductions in placebo groups [4]. The absolute difference translates to approximately 8 fewer hot flash episodes per week compared to placebo, based on meta-analysis data [10]. Persistence of benefit was documented through 24 weeks of continuous treatment [2].

Sleep Improvement:
Pooled analysis showed statistically significant reductions in VMS-attributed nighttime awakenings (P = 0.0049 at Week 4; P = 0.0001 at Week 12) and increased sleep duration (+31 to +37 minutes/night vs +16 to +27 min placebo). The absence of differential sedation or sleep-onset latency effects supports a VMS-mediated rather than direct hypnotic mechanism [11].

Weight and Sexual Function Neutrality:
A dedicated analysis of Phase 3 trial data (Portman et al., 2014) demonstrated no clinically significant weight gain and no adverse effects on sexual function with paroxetine 7.5 mg compared to placebo [12]. This stands in contrast to higher-dose paroxetine, which is associated with both weight gain and sexual dysfunction.

No Hormonal Effects:
Paroxetine 7.5 mg does not alter circulating estradiol, estrone, progesterone, FSH, or LH levels. It provides no bone protection, cardiovascular benefits, genitourinary improvement, or other systemic effects associated with estrogen replacement [1].

Risks, Side Effects & Safety

The Basics

At the 7.5 mg dose used for hot flashes, Brisdelle has a generally mild side effect profile. The most commonly reported side effects in clinical trials were headache (about 6% of women, compared to 5% on placebo), nausea or vomiting (about 4%, compared to 2%), and fatigue (about 3%, compared to 2%). Most of these side effects were mild to moderate and many resolved within the first few weeks.

Several concerns that are commonly associated with higher-dose SSRI therapy were specifically evaluated and found to be minimal at the 7.5 mg dose: weight gain was not significant, sexual dysfunction was not significantly different from placebo, and discontinuation symptoms upon stopping were minimal and did not require dose tapering in clinical trials.

That said, Brisdelle carries a boxed warning about suicidal thoughts and behaviors, which is a class-wide requirement for all SSRI medications. This warning is based on data from psychiatric populations (particularly children and young adults with depression), and the Brisdelle clinical trials excluded patients with psychiatric conditions. There is limited information about this risk specifically in menopausal women using Brisdelle, but providers should be aware.

Other risks to be aware of include serotonin syndrome (a rare but potentially serious reaction if Brisdelle is taken with other serotonergic medications), increased bleeding risk (especially if you take blood thinners, aspirin, or NSAIDs), and hyponatremia (low sodium, more common in elderly patients and those taking diuretics).

The Science

Common Adverse Reactions (Phase 3 Data, BRISDELLE vs Placebo):

Most treatment-emergent adverse events were mild or moderate in severity [2].

Serious Risks:

1. Suicidal Thoughts and Behaviors (Boxed Warning): Class-wide SSRI warning based on pediatric/young adult psychiatric data. BRISDELLE trials excluded psychiatric patients and enrolled primarily women aged 40-65+. Limited data on suicidality risk in the VMS population specifically [1].
2. Serotonin Syndrome: Potentially life-threatening. Risk increases with concurrent serotonergic agents (triptans, tramadol, lithium, other antidepressants, St. John's Wort, MAOIs). Symptoms include mental status changes, autonomic instability, neuromuscular abnormalities, and GI symptoms [1].
3. Bleeding Risk: SSRIs may impair platelet aggregation. Risk increases with concurrent anticoagulants, NSAIDs, or aspirin. Epidemiological data suggest upper GI bleeding risk is elevated with SSRI use [1].
4. Hyponatremia: Likely mediated by SIADH. More common in elderly patients, those on diuretics, and volume-depleted individuals. Monitor sodium if symptoms of confusion, weakness, or unsteadiness develop [1].
5. Bone Fracture Risk: Epidemiological studies report an association between SSRIs and bone fractures. The absolute risk increase and relevance at the 7.5 mg dose are not established [1].
6. Pregnancy Contraindication: BRISDELLE is contraindicated in pregnancy. Epidemiological data suggest first-trimester paroxetine exposure may increase risk of cardiac malformations. PPHN risk with third-trimester SSRI exposure [1].

CYP2D6 Inhibition and Tamoxifen (CRITICAL):
Paroxetine is a potent irreversible inhibitor of CYP2D6, which is the enzyme responsible for converting tamoxifen to its active metabolite endoxifen. Studies suggest that concurrent paroxetine use may reduce tamoxifen efficacy, measured by increased breast cancer relapse/mortality risk. For women taking tamoxifen for breast cancer treatment or prevention, the risk-benefit of Brisdelle versus the risk of impaired tamoxifen efficacy must be carefully weighed. Alternative SSRIs with less CYP2D6 inhibition (citalopram, escitalopram) or SNRIs (venlafaxine, desvenlafaxine) may be preferable in this population [1][5].

Discontinuation:
At the 7.5 mg dose, clinical trial data showed minimal discontinuation symptoms upon abrupt cessation without tapering [2][4]. This contrasts with higher SSRI doses, where discontinuation syndrome (dysphoric mood, irritability, dizziness, sensory disturbances, anxiety, insomnia) can be significant. Despite the clinical data, the prescribing label recommends a gradual reduction when possible, and some community reports describe discontinuation effects even at 7.5 mg [1].

Contraindications:

• Pregnancy
• Known hypersensitivity to paroxetine
• Concurrent MAOI use (or within 14 days)
• Concurrent thioridazine or pimozide use

Understanding your personal risk profile isn't a one-time calculation; it evolves as your treatment progresses. Doserly helps you see the bigger picture by analyzing side effect patterns over time, showing whether issues are resolving, persisting, or emerging as your body adjusts to therapy.

The app's analytics can reveal connections between side effects and specific aspects of your protocol, like whether symptoms correlate with a particular point in your patch cycle or a recent dose change. This kind of insight helps you and your provider make informed adjustments based on your actual experience, not just population-level averages.

Dosing & Treatment Protocols

The Basics

One of the simplest aspects of Brisdelle is the dosing: there is only one dose. You take a single 7.5 mg capsule at bedtime every day, with or without food. There is no starting dose to work up from, no titration schedule, and no dose adjustments. This simplicity is by design: the clinical trials tested only the 7.5 mg dose, and that is the only dose that received FDA approval for VMS.

Your healthcare provider may also prescribe generic paroxetine mesylate 7.5 mg, which is the same medication at a lower cost. Some providers prescribe paroxetine hydrochloride (the Paxil form) off-label at doses of 10 to 20 mg for hot flashes. These higher doses have also shown efficacy in clinical trials, but they come with a higher likelihood of side effects and are not FDA-approved for VMS.

The bedtime dosing recommendation comes from how the clinical trials were conducted. Taking it at bedtime may also help any mild drowsiness or nausea (if experienced) occur during sleep rather than during the day.

If you miss a dose, take it as soon as you remember. If it is almost time for the next dose, skip the missed one and resume your regular schedule. Do not take two capsules at the same time.

The Science

FDA-Approved Dosing:
The sole recommended oral dosage of BRISDELLE is 7.5 mg once daily at bedtime, with or without food. No dose titration is required [1].

Off-Label Paroxetine Dosing for VMS:

NAMS 2023 position statement notes that both salt forms have demonstrated efficacy, and initiating therapy with either paroxetine HCl 10 mg or paroxetine mesylate 7.5 mg is a reasonable approach [5].

Special Populations:

• Geriatric patients (>=65 years): 22% of Phase 3 participants were >=65 years. No overall differences in safety or effectiveness observed. No dose adjustment recommended [1].
• Hepatic impairment: Paroxetine plasma concentrations may be elevated. Use with caution, though no specific dose adjustment is defined for the 7.5 mg dose [1].
• Renal impairment: Plasma concentrations may be elevated in severe renal impairment. Use with caution [1].
• CYP2D6 poor metabolizers: 10-fold higher drug exposure at steady state. No specific dosing guidance for the 7.5 mg dose, but clinicians should be aware of increased side effect potential [1].

Duration of Treatment:
No defined treatment duration is established by the FDA. Ongoing treatment should be re-evaluated periodically. In the Phase 3 trials, efficacy was maintained through 24 weeks of continuous use [2].

Dosing protocols often change over the course of treatment, starting doses get adjusted, routes get switched, timing gets refined. Doserly maintains a complete history of every protocol change, giving you and your provider a clear picture of what has been tried and how each adjustment affected your symptoms.

The app's adherence analytics show your consistency patterns and can highlight whether missed doses or timing variations correlate with symptom changes. When your provider is considering a dose adjustment, having this data available makes the conversation more productive and the decision more informed.

What to Expect (Timeline)

Days 1-7: Most women tolerate the initial dose well. Some may experience mild nausea, headache, or slight dizziness in the first few days. These side effects typically resolve within the first week. Do not expect significant hot flash reduction yet; the drug needs time to reach steady-state levels in your bloodstream (approximately 14 days).

Weeks 2-4: Hot flash frequency typically begins to decrease. In clinical trials, statistically significant reductions in VMS frequency were already present at Week 4. Some women notice improvement sooner. Sleep disruption from night sweats should start to improve. Nausea and headache, if present initially, usually resolve by this point.

Months 1-3: Continued improvement in hot flash frequency and severity. By Week 12, the Phase 3 trials showed 54% reduction in nighttime awakenings (compared to 43% placebo). Sleep duration improvements of approximately 35 minutes per night were documented. Mood and anxiety improvements, if present, typically stabilize during this period.

Months 3-6: In the 24-week trial, treatment benefits were sustained and continued to build modestly. Nighttime awakenings reduced by 62% (compared to 43% placebo) at Week 24. If the medication is working well, this is a period of maintenance.

Ongoing Maintenance: The optimal duration of treatment has not been definitively established. Many women continue for 1-2 years or longer. Periodic reassessment with your healthcare provider is recommended to determine whether ongoing treatment is necessary, as VMS may naturally decrease over time.

If Stopping: Clinical trial data suggests that Brisdelle 7.5 mg can be stopped without tapering, and minimal discontinuation symptoms were reported. However, the prescribing information recommends a gradual reduction when possible. Hot flashes may return after stopping the medication.

Timing Hypothesis & Window of Opportunity

The timing hypothesis and window of opportunity concept apply specifically to menopausal hormone therapy, where evidence suggests that HRT initiated within 10 years of menopause onset or before age 60 has a more favorable risk-benefit profile than late initiation.

This framework does not apply to Brisdelle (paroxetine 7.5 mg) because it is a non-hormonal treatment. Paroxetine does not replace estrogen, does not interact with the hypothalamic-pituitary-ovarian axis in the same way as hormone therapy, and is not affected by the timing of initiation relative to menopause onset. It can be started at any point during the menopausal transition or post-menopause when VMS are bothersome, without the cardiovascular and other timing considerations that inform HRT initiation decisions.

For women considering whether to use Brisdelle versus hormone therapy, the timing hypothesis is relevant in the broader decision-making context. Women within the favorable window for HRT initiation (<10 years post-menopause, <60 years old) who have no contraindications may benefit more from hormone therapy, which offers systemic benefits beyond VMS relief. Brisdelle is particularly valuable for women outside this window, those with contraindications to HRT, or those who prefer a non-hormonal approach.

Interactions & Compatibility

Drug-Drug Interactions (Critical):

1. Tamoxifen (CYP2D6 interaction): Paroxetine is a potent irreversible CYP2D6 inhibitor. Tamoxifen requires CYP2D6 for conversion to its active metabolite endoxifen. Co-administration may reduce tamoxifen efficacy. Avoid in women taking tamoxifen. Consider citalopram, escitalopram, or venlafaxine as alternatives [1][5]. See also: Non-Hormonal Menopause Treatments
2. MAOIs: Contraindicated. Risk of serotonin syndrome. 14-day washout required in both directions [1].
3. Thioridazine and Pimozide: Contraindicated. CYP2D6 inhibition by paroxetine increases plasma levels, elevating risk of QT prolongation and potentially fatal cardiac arrhythmias [1].
4. Other Serotonergic Drugs: Risk of serotonin syndrome with triptans, tramadol, fentanyl, lithium, buspirone, tryptophan, other antidepressants (SSRIs, SNRIs, TCAs), and amphetamines [1].
5. Anticoagulants and NSAIDs: Increased bleeding risk. Monitor closely when co-administered with warfarin, aspirin, ibuprofen, naproxen, or other NSAIDs [1].
6. Other CYP2D6 Substrates: Paroxetine may increase plasma levels of codeine (paradoxically reducing analgesic effect by blocking conversion to morphine), atomoxetine, Type 1C antiarrhythmics (flecainide, propafenone), and certain other antidepressants [1].
7. Phenytoin: Monitor phenytoin levels when co-administered [1].
8. Fosamprenavir/Ritonavir: May significantly decrease paroxetine plasma levels [1].
9. Digoxin: Mean digoxin AUC decreased approximately 15% with concomitant paroxetine [1].

Supplement Interactions:

• St. John's Wort: Contraindicated. Serotonergic herb; risk of serotonin syndrome. Also a CYP3A4 inducer that may reduce paroxetine levels [1].
• Tryptophan/5-HTP: Not recommended due to serotonin excess risk [1].
• Omega-3 fatty acids, Vitamin D, Calcium, Magnesium: No known interactions; safe to use concurrently.

Lifestyle Factors:

• Alcohol: Patients should be advised to avoid alcohol while taking paroxetine [1].
• Smoking: No specific pharmacokinetic interaction documented at this dose.
• Grapefruit: Paroxetine is metabolized primarily by CYP2D6, not CYP3A4. Grapefruit interaction is not clinically significant.

Cross-References:

• Fezolinetant (Veozah) (alternative non-hormonal option)
• Elinzanetant (Lynkuet) (alternative non-hormonal option)
• Gabapentin for Menopause (alternative non-hormonal option)
• Non-Hormonal Menopause Treatments (overview)

Decision-Making Framework

Deciding whether Brisdelle is right for you involves weighing several factors with your healthcare provider.

Who is Brisdelle most appropriate for?

• Women with moderate to severe hot flashes who cannot take hormone therapy (breast cancer history or risk, VTE history, cardiovascular disease, other contraindications)
• Women who prefer not to use hormonal treatment
• Women who have tried hormone therapy and experienced intolerable side effects
• Women outside the favorable timing window for HRT initiation who still have bothersome VMS

Who should avoid Brisdelle?

• Women currently taking tamoxifen (CYP2D6 interaction reduces tamoxifen efficacy)
• Women taking MAOIs or within 14 days of MAOI use
• Women with known hypersensitivity to paroxetine
• Pregnant women
• Women who may benefit more from hormone therapy (within timing window, no contraindications) should discuss HRT as a potentially more effective first-line option

Questions to Ask Your Provider:

• "Am I a candidate for hormone therapy, or are there reasons I should consider a non-hormonal approach?"
• "Given my other medications, are there any interactions to worry about with Brisdelle?"
• "If Brisdelle does not work well enough, what are my other non-hormonal options?"
• "How long should I plan to take this medication?"
• "What should I expect in terms of side effects in the first few weeks?"
• "Is the generic version (paroxetine mesylate 7.5 mg) available and appropriate for me?"

Finding a Menopause Specialist:
If your current provider is unfamiliar with the range of menopause treatment options, consider seeking a Menopause Society (formerly NAMS) Certified Menopause Practitioner. These providers have specialized training in both hormonal and non-hormonal approaches to menopause management. The provider directory is available at menopause.org.

Administration & Practical Guide

How to Take Brisdelle:

• Swallow the capsule whole at bedtime
• Take with or without food
• Take at the same time each night for consistency
• Do not open, crush, or dissolve the capsule

Missed Dose:
Take the missed dose as soon as you remember. If it is close to the time for your next dose, skip the missed dose and resume your regular schedule. Do not double up.

Storage:

• Store at room temperature (68-77F / 20-25C)
• Protect from light
• Keep dry
• Keep out of reach of children

Practical Tips from Clinical Experience:

• Some women experience mild nausea in the first week. Taking with a small snack at bedtime may help.
• If drowsiness occurs, the bedtime dosing timing works in your favor.
• Keep a symptom diary for the first 4-6 weeks to track hot flash frequency and any side effects, as this helps your provider assess effectiveness.
• The capsule is pink and clearly marked. Do not confuse with higher-dose Paxil tablets if you have other paroxetine products in the household.

Monitoring & Lab Work

Pre-Treatment:

• No specific laboratory testing is required before starting Brisdelle
• Review medication list for CYP2D6-dependent drugs, serotonergic medications, and anticoagulants
• Screen for bipolar disorder history (SSRIs can precipitate mania)
• Assess bleeding risk factors

Initial Follow-Up (4-8 weeks):

• Assess VMS response (frequency and severity)
• Evaluate side effects (headache, nausea, fatigue)
• Monitor for signs of serotonin syndrome in patients on concurrent serotonergic medications
• Assess mood and mental health status

Ongoing Monitoring:

• Periodic reassessment of VMS and need for continued treatment
• Monitor for hyponatremia in elderly patients or those on diuretics (symptoms: confusion, weakness, unsteadiness)
• Monitor bleeding events in patients on concurrent anticoagulants or NSAIDs
• Reassess annually whether VMS symptoms have diminished enough to consider discontinuation

No Routine Lab Monitoring Required:
Unlike some medications, Brisdelle does not require routine blood work (no liver function tests, hormone levels, or drug levels). Monitoring is primarily clinical (symptom assessment and side effect evaluation).

Complementary Approaches & Lifestyle

For women using Brisdelle, several evidence-based complementary strategies can support overall menopause management:

Cognitive-Behavioral Therapy (CBT):
CBT for hot flashes is recommended by NAMS (Level I evidence). It does not reduce hot flash frequency but significantly reduces the perceived bother and interference with daily life. CBT can be used alongside Brisdelle [5].

Exercise:
While exercise is not recommended by NAMS specifically for VMS reduction, regular physical activity supports cardiovascular health, bone density, mood, and weight management during menopause. Weight-bearing and resistance exercise are particularly important for bone health, which Brisdelle does not address.

Weight Management:
Weight loss is recommended by NAMS (Level II-III evidence) for VMS reduction. Higher body weight is associated with more frequent and severe hot flashes. A combined approach of Brisdelle plus lifestyle modification may be beneficial [5].

Supplements:

• Vitamin D and calcium: important for bone health during menopause (Brisdelle provides no bone protection)
• Magnesium: may support sleep quality
• Herbal supplements (black cohosh, soy, phytoestrogens): NOT recommended by NAMS for VMS; evidence does not support efficacy [5]
• St. John's Wort: AVOID due to serotonin syndrome risk with Brisdelle

Sleep Hygiene:
Keep the bedroom cool, use moisture-wicking bedding, maintain consistent sleep/wake times, limit caffeine after noon, and consider a cooling pillow or mattress pad. These measures complement Brisdelle's sleep-improving effects.

Pelvic Floor Therapy:
For genitourinary symptoms of menopause, which Brisdelle does not address, pelvic floor physical therapy can help with urinary incontinence and may improve sexual function.

Non-Hormonal Prescription Alternatives:
If Brisdelle is insufficient, other non-hormonal prescription options include gabapentin, oxybutynin, fezolinetant (Veozah), and elinzanetant (Lynkuet). See Non-Hormonal Menopause Treatments for a comprehensive comparison.

Stopping HRT / Discontinuation

As a non-hormonal treatment, stopping Brisdelle does not carry the same considerations as stopping hormone therapy. There is no increased cardiovascular, bone, or breast cancer risk associated with stopping, and no hormonal withdrawal occurs.

When to Consider Stopping:

• VMS symptoms have naturally diminished (common 3-7+ years after menopause)
• Side effects outweigh benefits
• A more effective treatment has been identified
• Regular reassessment (at least annually) to determine ongoing need

How to Stop:
Clinical trial data suggests that paroxetine 7.5 mg can be discontinued abruptly without clinically significant discontinuation symptoms [2]. The prescribing information, however, recommends gradual dose reduction when possible [1]. Given that 7.5 mg is already the lowest available dose, "tapering" may involve taking the capsule every other day for 1-2 weeks before stopping entirely, though this approach has not been formally studied.

What to Expect After Stopping:

• Hot flashes and night sweats may return. The timeline for recurrence varies; some women experience return of symptoms within days, others within weeks.
• Discontinuation symptoms (if any) at this dose are typically mild: possible irritability, dizziness, headache, or sensory disturbances. These usually resolve within 1-2 weeks.
• Monitor symptoms for 4-6 weeks after stopping to assess whether VMS are still problematic.

Transitioning to Other Treatments:
If VMS return after stopping Brisdelle, options include restarting Brisdelle, switching to another non-hormonal treatment (fezolinetant, gabapentin, venlafaxine), or considering hormone therapy if now appropriate and no contraindications exist.

Special Populations & Situations

Breast Cancer Survivors

Brisdelle was developed in large part for this population, as hormone therapy is generally contraindicated. However, a critical caveat exists: paroxetine is a potent CYP2D6 inhibitor and should NOT be used concurrently with tamoxifen. For breast cancer survivors taking tamoxifen, citalopram, escitalopram, or venlafaxine are preferred alternatives. For breast cancer survivors not on tamoxifen, Brisdelle may be appropriate [1][5].

Premature Ovarian Insufficiency (POI)

Women with POI (menopause before age 40) typically benefit most from hormone replacement to provide the estrogen their bodies need for bone, cardiovascular, and overall health until the typical age of menopause (~51). Brisdelle addresses only VMS and should not be considered a substitute for HRT in POI unless HRT is contraindicated.

Surgical Menopause / Oophorectomy

Meta-analysis data confirms Brisdelle's efficacy in surgically menopausal women (MD -7.63 episodes/week vs placebo) [10]. However, women who undergo bilateral oophorectomy experience abrupt, severe hormone depletion and typically benefit most from hormone replacement. Brisdelle may be appropriate as adjunctive therapy or for women who cannot take HRT.

Geriatric Patients (>=65 years)

22% of Phase 3 trial participants were 65 and older, with no significant differences in safety or efficacy observed. Hyponatremia risk may be elevated in elderly patients, particularly those on diuretics [1].

VTE History

Brisdelle is a reasonable option for women with a history of venous thromboembolism who cannot use systemic estrogen. Paroxetine does not increase VTE risk. However, epidemiological data suggest a possible association between SSRIs and bone fractures, which may be relevant for this population [1].

Patients on Multiple Medications

The CYP2D6 inhibition by paroxetine requires careful medication reconciliation. Patients on multiple medications should have a comprehensive drug interaction review before starting Brisdelle.

Regulatory, Insurance & International

United States (FDA):

• FDA-approved June 28, 2013 (NDA 204516)
• Indication: Treatment of moderate to severe VMS associated with menopause
• Carries class-wide SSRI boxed warning for suicidal thoughts and behaviors
• Generic paroxetine mesylate 7.5 mg capsules are available
• Branded Brisdelle has been marketed by several companies since approval (Noven, Sebela, now Legacy Pharma)
• Insurance coverage varies; some plans cover generics but not the branded product
• Typical retail cost: branded Brisdelle can exceed $200/month without insurance; generic versions are substantially less expensive

United Kingdom (MHRA):
Brisdelle (paroxetine 7.5 mg for VMS) is not separately licensed in the UK. Paroxetine is available at psychiatric doses. Some UK prescribers may use low-dose paroxetine off-label for VMS.

Canada (Health Canada):
No specific paroxetine 7.5 mg VMS product is approved in Canada. Off-label use of paroxetine for VMS occurs.

Australia (TGA):
No specific VMS indication for paroxetine 7.5 mg in Australia.

European Union (EMA):
No centralized EU approval for paroxetine specifically at 7.5 mg for VMS.

Frequently Asked Questions

Is Brisdelle the same as Paxil?
Brisdelle contains the same active ingredient (paroxetine) as Paxil, but at a much lower dose and for a completely different purpose. Brisdelle provides 7.5 mg of paroxetine mesylate for hot flashes; Paxil provides 20-60 mg of paroxetine hydrochloride for depression and anxiety disorders. The side effect profiles differ significantly at these different doses.

Will Brisdelle make me gain weight?
Clinical trial data at the 7.5 mg dose showed no clinically significant weight gain compared to placebo. This is notably different from higher-dose paroxetine, which is associated with weight gain.

Will Brisdelle affect my sex drive?
At the 7.5 mg dose, clinical trials found no significant adverse effects on sexual function compared to placebo. Higher-dose paroxetine is commonly associated with sexual dysfunction, but this does not appear to apply at the low dose used for VMS.

How quickly does Brisdelle work?
Most women notice improvement within 2-4 weeks. The drug reaches steady-state blood levels in about 14 days. Some women report improvement sooner, while others may need 4-6 weeks for full effect.

Can I take Brisdelle with my hormone therapy?
There is no pharmacological contraindication to using Brisdelle concurrently with hormone therapy. However, if HRT is adequately controlling your hot flashes, adding Brisdelle is unlikely to provide additional benefit. Some women may use both during an HRT transition period. Discuss with your healthcare provider.

Can I take Brisdelle if I have a history of depression?
Brisdelle was not studied in women with active psychiatric conditions. If you have a history of depression, discuss the risks and benefits with your provider. The 7.5 mg dose is subtherapeutic for depression, so it should not be relied upon for mood disorder management.

Is it hard to stop taking Brisdelle?
Clinical trial data showed minimal discontinuation symptoms at the 7.5 mg dose. However, some individuals may experience mild symptoms when stopping. Your provider may recommend a brief taper (every-other-day dosing for 1-2 weeks) as a precaution.

Does Brisdelle interact with tamoxifen?
Yes. Paroxetine is a potent inhibitor of CYP2D6, the enzyme that converts tamoxifen to its active form. Women taking tamoxifen should not use Brisdelle. Alternative non-hormonal options include citalopram, escitalopram, venlafaxine, gabapentin, or fezolinetant.

Is there a generic version?
Yes. Generic paroxetine mesylate 7.5 mg capsules are available and are typically much less expensive than branded Brisdelle.

How long can I take Brisdelle?
There is no established maximum treatment duration. Clinical trials demonstrated safety and efficacy through 24 weeks. Many women use it for 1-2 years or longer. Periodic reassessment with your provider is recommended.

Is Brisdelle as effective as hormone therapy for hot flashes?
No. Hormone therapy typically reduces hot flash frequency by 75-95%. Brisdelle provides a more modest 33-65% reduction (10-25% greater than placebo). However, for women who cannot use HRT, Brisdelle provides meaningful relief.

Can I drink alcohol while taking Brisdelle?
The prescribing information recommends avoiding alcohol while taking paroxetine.

Myth vs. Fact

Myth: Brisdelle is just a repackaged antidepressant prescribed to dismiss menopausal women's symptoms.
Fact: While paroxetine is indeed an antidepressant at higher doses, Brisdelle (7.5 mg) was specifically developed, studied, and FDA-approved for vasomotor symptoms. Two Phase 3 trials with over 1,100 women demonstrated efficacy for hot flash reduction. The NAMS classifies SSRIs as Level I evidence for VMS treatment. The development of a non-hormonal VMS treatment addresses a genuine unmet medical need for women who cannot use hormone therapy [2][5].

Myth: Taking Brisdelle will cause the same side effects as taking Paxil for depression.
Fact: The side effect profile at 7.5 mg is substantially different from the 20-60 mg doses used for psychiatric conditions. Clinical trial data showed no significant weight gain, no significant sexual dysfunction, and minimal discontinuation symptoms at the 7.5 mg dose. The dose matters enormously for SSRI side effects [2][12].

Myth: Once you start Brisdelle, you can never stop because withdrawal is too severe.
Fact: Phase 3 trial data showed minimal discontinuation symptoms when stopping Brisdelle 7.5 mg without tapering. This is distinctly different from the discontinuation syndrome associated with higher-dose SSRI use. While some individuals may experience mild symptoms, clinical evidence does not support the "impossible to stop" characterization at this dose [2][4].

Myth: Brisdelle is just as effective as hormone therapy for hot flashes.
Fact: Hormone therapy remains the most effective treatment for VMS, typically reducing hot flash frequency by 75-95%. Brisdelle provides a more modest but clinically meaningful reduction of 33-65% (10-25% greater than placebo). Brisdelle is an important option for women who cannot use HRT, not a replacement for it [5].

Myth: Non-hormonal treatments are unnecessary because natural remedies work just as well.
Fact: The NAMS 2023 position statement found that supplements and herbal remedies (including black cohosh, soy, evening primrose oil, and phytoestrogens) are NOT recommended for VMS based on Level I-II evidence showing insufficient efficacy. Prescription non-hormonal options like paroxetine have Level I evidence supporting their use [5].

Myth: You cannot take Brisdelle if you have had breast cancer.
Fact: Brisdelle may actually be an appropriate option for breast cancer survivors experiencing hot flashes, with one critical exception: it should NOT be used by women taking tamoxifen because paroxetine inhibits the CYP2D6 enzyme needed to activate tamoxifen. Breast cancer survivors on aromatase inhibitors or who have completed tamoxifen therapy may safely use Brisdelle. Alternative non-hormonal options are available for those on tamoxifen [1][5].

Myth: SSRIs for menopause symptoms mean your doctor thinks your hot flashes are "just in your head."
Fact: Hot flashes are a real, physiological phenomenon caused by changes in the hypothalamic thermoregulatory center during menopause. SSRIs work on this thermoregulatory mechanism through serotonergic pathways, not by treating a psychological condition. The FDA specifically noted that Brisdelle is not indicated for any psychiatric condition [1].

Myth: All SSRIs work equally well for hot flashes.
Fact: While several SSRIs and SNRIs have shown efficacy for VMS, only paroxetine mesylate 7.5 mg is FDA-approved for this indication. The various agents differ in their efficacy, CYP2D6 inhibition potency (critical for tamoxifen interaction), and side effect profiles. Choice should be individualized based on a woman's medication list and medical history [5].

Sources & References

Clinical Guidelines

1. BRISDELLE (paroxetine) capsules prescribing information. Legacy Pharma USA, Inc. Revised February 2025. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=502311b3-b617-4cbd-a3ab-a60f2c62880a
2. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573-590. doi: 10.1097/GME.0000000000002200

Landmark Trials

1. Simon JA, Portman DJ, Kaunitz AM, et al. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: Two randomized controlled trials. Menopause. 2013;20(10):1027-1035. doi: 10.1097/GME.0b013e3182a66aa7

Systematic Reviews & Meta-Analyses

1. Riemma G, Schiattarella A, La Verde M, et al. Efficacy of Low-Dose Paroxetine for the Treatment of Hot Flushes in Surgical and Physiological Postmenopausal Women: Systematic Review and Meta-Analysis of Randomized Trials. Medicina. 2019;55(9):554. doi: 10.3390/medicina55090554

Secondary Analyses

1. Pinkerton JV, Joffe H, Kazempour K, et al. Low-dose paroxetine (7.5 mg) improves sleep in women with vasomotor symptoms associated with menopause. Menopause. 2015;22(1):50-58. doi: 10.1097/GME.0000000000000311
2. Portman DJ, Kaunitz AM, Kazempour K, et al. Effects of low-dose paroxetine 7.5 mg on weight and sexual function during treatment of vasomotor symptoms associated with menopause. Menopause. 2014;21(10):1082-1090. doi: 10.1097/GME.0000000000000210

Clinical Reviews

1. David PS. A Clinical Review on Paroxetine and Emerging Therapies for the Treatment of Vasomotor Symptoms. Int J Womens Health. 2022;14:255-272. doi: 10.2147/IJWH.S282396

Government/Institutional Sources

1. FDA Approves Brisdelle - First Non-Hormonal Treatment for Hot Flashes Associated with Menopause. FDA News Release. June 28, 2013. Available at: https://www.drugs.com/newdrugs/fda-approves-brisdelle-first-non-hormonal-hot-flashes-associated-menopause-3834.html

Mechanism & Physiology

1. Deecher DC, Dorries K. Understanding the pathophysiology of vasomotor symptoms (hot flushes and night sweats) that occur in perimenopause, menopause, and postmenopause life stages. Arch Womens Ment Health. 2007;10(6):247-257. doi: 10.1007/s00737-007-0209-5
2. Freedman RR. Menopausal hot flashes: mechanisms, endocrinology, treatment. J Steroid Biochem Mol Biol. 2014;142:115-120. doi: 10.1016/j.jsbmb.2013.08.010
3. Rance NE, Dacks PA, Mittelman-Smith MA, et al. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes. Front Neuroendocrinol. 2013;34(3):211-227. doi: 10.1016/j.yfrne.2013.07.003
4. Bertelsen KM, Venkatakrishnan K, Von Moltke LL, et al. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos. 2003;31(3):289-293. doi: 10.1124/dmd.31.3.289

Related Guides & Cross-Links

Same Category (Non-Hormonal Prescription Medications)

• Fezolinetant (Veozah) — NK3 receptor antagonist; FDA-approved 2023 for VMS
• Elinzanetant (Lynkuet) — NK3 receptor antagonist; FDA-approved for VMS
• Gabapentin for Menopause — Anticonvulsant used off-label for VMS
• Clonidine for Menopause — Alpha-2 agonist; not recommended by NAMS 2023
• Ospemifene (Osphena) — SERM for GSM (different indication)
• Tibolone (Livial) — Synthetic steroid (not available in US)

Treatment Overview Guides

• Non-Hormonal Menopause Treatments — Comprehensive comparison
• Getting Started with HRT — For women considering hormonal options

Hormonal Treatment Options (for comparison)

• 17B-Estradiol (Bioidentical) — First-line HRT for VMS
• Micronized Progesterone (Prometrium) — Progestogen component of HRT
• Conjugated Equine Estrogens (Premarin) — Older estrogen formulation

Condition Guides

• Menopause — Comprehensive menopause overview
• Surgical Menopause — Relevant for post-oophorectomy VMS

[!DISCLAIMER]

Educational Purpose: This guide provides educational information about paroxetine low-dose (Brisdelle) for menopausal vasomotor symptoms. It is not medical advice and does not replace consultation with a qualified healthcare provider.

Medical Supervision Required: Brisdelle is a prescription medication. All treatment decisions should be made in partnership with a healthcare provider who can evaluate your individual medical history, current medications, and risk factors.

AI Content Disclosure: This guide was generated with AI assistance from research sources and clinical data. While every effort has been made to ensure accuracy, readers should verify critical information with primary sources and their healthcare providers.

Individual Risk Assessment: The efficacy, side effects, and risks described in this guide represent population-level data from clinical trials. Individual responses vary. Your healthcare provider can help assess your personal risk-benefit profile.

Clinical Judgment: Nothing in this guide should override the clinical judgment of your healthcare provider. Treatment decisions involve weighing factors specific to your situation that cannot be captured in a general guide.

Source Attribution: All factual claims are sourced from peer-reviewed literature, FDA prescribing information, and clinical guidelines. See Section 24 for full citations.